ABSTRACT
Brain pathologies evoked by thiamine deficiency can be aggravated by mild zinc excess. Cholinergic neurons are the most susceptible to such cytotoxic signals. Sub-toxic zinc excess aggravates the injury of neuronal SN56 cholinergic cells under mild thiamine deficiency. The excessive cell loss is caused by Zn interference with acetyl-CoA metabolism. The aim of this work was to investigate whether and how astroglial C6 cells alleviated the neurotoxicity of Zn to cultured SN56 cells in thiamine-deficient media. Low Zn concentrations did not affect astroglial C6 and primary glial cell viability in thiamine-deficient conditions. Additionally, parameters of energy metabolism were not significantly changed. Amprolium (a competitive inhibitor of thiamine uptake) augmented thiamine pyrophosphate deficits in cells, while co-treatment with Zn enhanced the toxic effect on acetyl-CoA metabolism. SN56 cholinergic neuronal cells were more susceptible to these combined insults than C6 and primary glial cells, which affected pyruvate dehydrogenase activity and the acetyl-CoA level. A co-culture of SN56 neurons with astroglial cells in thiamine-deficient medium eliminated Zn-evoked neuronal loss. These data indicate that astroglial cells protect neurons against Zn and thiamine deficiency neurotoxicity by preserving the acetyl-CoA level.
Subject(s)
Cholinergic Neurons/metabolism , Neuroglia/metabolism , Thiamine Deficiency/prevention & control , Zinc/toxicity , Animals , Cell Line, Tumor , Culture Media , Mice , Thiamine/metabolism , Thiamine/pharmacology , Thiamine Deficiency/metabolismABSTRACT
BACKGROUND: Hypophosphatemia may be a useful biomarker to identify thiamine deficiency in critically ill enterally-fed patients. The objective was to determine whether intravenous thiamine affects blood lactate, biochemical and clinical outcomes in this group. METHOD: This randomized clinical trial was conducted across 5 Intensive Care Units. Ninety critically ill adult patients with a serum phosphate ≤0.65 mmol/L within 72 h of commencing enteral nutrition were randomized to intravenous thiamine (200 mg every 12 h for up to 14 doses) or usual care (control). The primary outcome was blood lactate over time and data are median [IQR] unless specified. RESULTS: Baseline variables were well balanced (thiamine: lactate 1.2 [1.0, 1.6] mmol/L, phosphate 0.56 [0.44, 0.64] mmol/L vs. control: lactate 1.0 [0.8, 1.3], phosphate 0.54 [0.44, 0.61]). Patients randomized to the intervention received a median of 11 [7.5, 13.5] doses for a total of 2200 [1500, 2700] mg of thiamine. Blood lactate over the entire 7 days of treatment was similar between groups (mean difference = -0.1 (95 % CI -0.2 to 0.1) mmol/L; P = 0.55). The percentage change from lactate pre-randomization to T = 24 h was not statistically different (thiamine: -32 (-39, -26) vs. control: -24 (-31, -16) percent, P = 0.09). Clinical outcomes were not statistically different (days of vasopressor administration: thiamine 2 [1, 4] vs. control 2 [0, 5.5] days; P = 0.37, and deaths 9 (21 %) vs. 5 (11 %); P = 0.25). CONCLUSIONS: In critically ill enterally-fed patients who developed hypophosphatemia, intravenous thiamine did not cause measurable differences in blood lactate or clinical outcomes. TRIAL REGISTRATION: Australian and New Zealand Clinical Trials Registry (ACTRN12619000121167).
Subject(s)
Enteral Nutrition/adverse effects , Hypophosphatemia/drug therapy , Thiamine Deficiency/prevention & control , Thiamine/administration & dosage , Administration, Intravenous , Adult , Aged , Biomarkers/blood , Critical Illness/therapy , Female , Humans , Hypophosphatemia/etiology , Intensive Care Units , Lactic Acid/blood , Male , Middle Aged , Phosphates/blood , Thiamine Deficiency/etiology , Treatment OutcomeABSTRACT
Women reliant on mostly rice-based diets can have inadequate thiamine intake, placing breastfed infants at risk of thiamine deficiency and, in turn, physical and cognitive impairments. We investigated the impact of maternal thiamine supplementation doses on infants' cognitive, motor, and language development across the first year. In this double-blind, four-parallel-arm, randomized controlled trial, healthy mothers of exclusively breastfed newborn infants were recruited in Kampong Thom, Cambodia. At 2 weeks postnatal, women (n = 335) were randomized to one of four treatment groups to consume one capsule/day with varying amounts of thiamine for 22 weeks: 0, 1.2, 2.4, and 10 mg. At 2, 12, 24, and 52 weeks of age, infants were assessed with the Mullen Scales of Early Learning (MSEL) and the Caregiver Reported Early Development Instrument (CREDI). Multiple regression and mixed effects modeling suggest that by 6 months of age, the highest maternal thiamine dose (10 mg/day) held significant benefits for infants' language development, but generally not for motor or visual reception development. Despite having achieved standardized scores on the MSEL that approximated U.S. norms by 6 months, infants showed a significant drop relative to these norms in both language domains following trial completion, indicating that nutritional interventions beyond 6 months may be necessary.
Subject(s)
Breast Feeding , Child Development , Cognition , Dietary Supplements , Thiamine Deficiency/epidemiology , Thiamine Deficiency/prevention & control , Thiamine/administration & dosage , Age Factors , Cambodia/epidemiology , Female , Health Impact Assessment , Humans , Infant , Infant, Newborn , Public Health Surveillance , Thiamine/metabolism , Thiamine Deficiency/etiologyABSTRACT
Severe thiamine (vitamin B1 ) deficiency is generally regarded as a problem affecting mostly infants in low-income communities of Southeast Asia and adult alcoholics regardless of their location. However, recent scholarship shows that the disorders associated with thiamine deficiency may also affect heretofore unsuspected populations, and that the scope of disorders, including some long-lasting neurocognitive consequences, is broader than previously thought.
Subject(s)
Thiamine Deficiency/epidemiology , Beriberi/diagnosis , Beriberi/epidemiology , Beriberi/etiology , Beriberi/prevention & control , Biomarkers , Disease Management , Disease Susceptibility , Global Health , Humans , Population Surveillance , Risk Factors , Thiamine Deficiency/diagnosis , Thiamine Deficiency/etiology , Thiamine Deficiency/prevention & controlABSTRACT
In 2014, there was an outbreak of beriberi on Kuria, a remote atoll in Kiribati, a small Pacific Island nation. A thiamine-poor diet consisting mainly of rice, sugar, and small amounts of fortified flour was likely to blame. We aimed to design a food fortification strategy to improve thiamine intakes in Kuria. We surveyed all 104 households on Kuria with a pregnant woman or a child 0-59 months. Repeat 24-h dietary recalls were collected from 90 men, 17 pregnant, 44 lactating, and 41 other women of reproductive age. The prevalence of inadequate thiamine intakes was >30% in all groups. Dietary modeling predicted that rice or sugar fortified at a rate of 0.3 and 1.4 mg per 100 g, respectively, would reduce the prevalence of inadequate thiamine intakes to <2.5% in all groups. Fortification is challenging because Kiribati imports food from several countries, depending on price and availability. One exception is flour, which is imported from Fiji. Although resulting in less coverage than rice or sugar, fortifying wheat flour with an additional 3.7 mg per 100 g would reduce the prevalence of inadequacy to under 10%. Kiribati is small and has limited resources; thus, a regional approach to thiamine fortification is needed.
Subject(s)
Food, Fortified , Thiamine Deficiency/epidemiology , Thiamine Deficiency/prevention & control , Thiamine , Cross-Sectional Studies , Disease Management , Female , Humans , Male , Micronesia/epidemiology , Pregnancy , Prevalence , Public Health Surveillance , Surveys and Questionnaires , Thiamine/administration & dosage , Thiamine Deficiency/etiologyABSTRACT
Thiamine (vitamin B1 ) is an essential micronutrient in energy metabolism and cognitive and neurological health. Thiamine deficiency disorders (TDDs) have a range of clinical presentations that result in various morbidities and can be fatal if not promptly recognized and treated, especially in infants. To intervene, thiamine intakes by breastfeeding mothers and others at risk of thiamine deficiency should be increased to ensure adequate thiamine intake. Although thiamine fortification programs have a long history in high-income countries, there are few mandatory fortification programs to address TDDs in low- and middle-income countries (LMICs), particularly in the regions of greatest concern, South and Southeast Asia. This review highlights essential aspects for consideration in the development of a mandatory fortification program in LMICs, including an overview of the data required to model fortification dosing schemes, available thiamine fortificants, and potential fortification vehicles, as well as identifies current knowledge gaps.
Subject(s)
Dietary Supplements , Food, Fortified , Thiamine Deficiency/epidemiology , Thiamine Deficiency/prevention & control , Thiamine/administration & dosage , Developing Countries , Disease Susceptibility , Global Health , Humans , Micronutrients , Nutritional Requirements , Population Surveillance , Socioeconomic Factors , Thiamine/metabolism , Thiamine Deficiency/etiology , Thiamine Deficiency/therapyABSTRACT
Thiamine deficiency is a public health issue in Cambodia. Thiamine fortification of salt has been proposed; however, the salt intake of lactating women, the target population, is currently unknown. We estimated salt intakes among lactating women (<6 months postpartum) using three methods: repeat observed-weighed intake records and 24-h urinary sodium excretions (n = 104), and household salt disappearance (n = 331). Usual salt intake was estimated by adjusting for intraindividual intakes using the National Cancer Institute method, and a thiamine salt fortification scenario was modeled using a modified estimated average requirement (EAR) cut-point method. Unadjusted salt intake from observed intakes was 9.3 (8.3-10.3) g/day, which was not different from estimated salt intake from urinary sodium excretions, 9.0 (8.4-9.7) g/day (P = 0.3). Estimated salt use from household salt disappearance was 11.3 (10.7-11.9) g/person/day. Usual (adjusted) salt intake from all sources was 7.7 (7.4-8.0) g/day. Assuming no stability losses, a modeled fortification dose of 275 mg thiamine/kg salt could increase thiamine intakes from fortified salt to 2.1 (2.0-2.2) mg/day, with even low salt consumers reaching the EAR of 1.2 mg/day from fortified salt alone. These findings, in conjunction with future sensory and stability research, can inform a potential salt fortification program in Cambodia.
Subject(s)
Dietary Supplements , Food, Fortified , Sodium Chloride, Dietary/administration & dosage , Thiamine Deficiency/epidemiology , Thiamine Deficiency/prevention & control , Thiamine/administration & dosage , Adult , Cambodia/epidemiology , Disease Management , Disease Susceptibility , Family Characteristics , Female , Humans , Male , Pregnancy , Public Health Surveillance , Sociodemographic Factors , Thiamine/blood , Thiamine/metabolism , Thiamine Deficiency/etiologyABSTRACT
Thiamine is a crucial cofactor involved in the maintenance of carbohydrate metabolism and participates in multiple cellular metabolic processes. Although thiamine can be obtained from various food sources, some common food groups are deficient in thiamine, and it can be denatured by high temperature and pH. Additionally, different drugs can alter thiamine metabolism. In addition, the half-life of thiamine in the body is between 1 and 3 weeks. All these factors could provide an explanation for the relatively short period needed to develop thiamine deficiency and observe the consequent clinical symptoms. Thiamine deficiency could lead to neurological and cardiological problems. These clinical conditions could be severe or even fatal. Marginal deficiency too may promote weaker symptoms that might be overlooked. Patients undergoing upper gastrointestinal or pancreatic surgery could have or develop thiamine deficiency for many different reasons. To achieve the best outcome for these patients, we strongly recommend the execution of both an adequate preoperative nutritional assessment, which includes thiamine evaluation, and a close nutritional follow up to avoid a nutrient deficit in the postoperative period.
Subject(s)
Digestive System Surgical Procedures/adverse effects , Nutritional Status , Thiamine Deficiency/blood , Thiamine/blood , Humans , Thiamine Deficiency/etiology , Thiamine Deficiency/prevention & controlABSTRACT
Thiamine (vitamin B1) is a precursor of the well-known coenzyme of central metabolic pathways thiamine diphosphate (ThDP). Highly intense glucose oxidation in the brain requires ThDP-dependent enzymes, which determines the critical significance of thiamine for neuronal functions. However, thiamine can also act through the non-coenzyme mechanisms. The well-known facilitation of acetylcholinergic neurotransmission upon the thiamine and acetylcholine co-release into the synaptic cleft has been supported by the discovery of thiamine triphosphate (ThTP)-dependent phosphorylation of the acetylcholine receptor-associated protein rapsyn, and thiamine interaction with the TAS2R1 receptor, resulting in the activation of synaptic ion currents. The non-coenzyme regulatory binding of thiamine compounds has been demonstrated for the transcriptional regulator p53, poly(ADP-ribose) polymerase, prion protein PRNP, and a number of key metabolic enzymes that do not use ThDP as a coenzyme. The accumulated data indicate that the molecular mechanisms of the neurotropic action of thiamine are far broader than it has been originally believed, and closely linked to the metabolism of thiamine and its derivatives in animals. The significance of this topic has been illustrated by the recently established competition between thiamine and the antidiabetic drug metformin for common transporters, which can be the reason for the thiamine deficiency underlying metformin side effects. Here, we also discuss the medical implications of the research on thiamine, including the role of thiaminases in thiamine reutilization and biosynthesis of thiamine antagonists; molecular mechanisms of action of natural and synthetic thiamine antagonists, and biotransformation of pharmacological forms of thiamine. Given the wide medical application of thiamine and its synthetic forms, these aspects are of high importance for medicine and pharmacology, including the therapy of neurodegenerative diseases.
Subject(s)
Hypoglycemic Agents/metabolism , Metformin/metabolism , Thiamine/analogs & derivatives , Thiamine/metabolism , Vitamin B Complex/metabolism , Animals , Brain/metabolism , Coenzymes , Humans , Hypoglycemic Agents/administration & dosage , Hypoglycemic Agents/adverse effects , Metformin/administration & dosage , Metformin/adverse effects , Mice , Phosphorylation , Protein Transport/physiology , Rats , Thiamine/adverse effects , Thiamine/pharmacology , Thiamine Deficiency/etiology , Thiamine Deficiency/prevention & control , Thiamine Pyrophosphate/metabolism , Vitamin B Complex/adverse effects , Vitamin B Complex/pharmacologyABSTRACT
INTRODUCTION: Thiamine (vitamin B1) deficiency remains a concern in Cambodia where women with low thiamine intake produce thiamine-poor milk, putting their breastfed infants at risk of impaired cognitive development and potentially fatal infantile beriberi. Thiamine fortification of salt is a potentially low-cost, passive means of combating thiamine deficiency; however, both the dose of thiamine required to optimise milk thiamine concentrations as well as usual salt intake of lactating women are unknown. METHODS AND ANALYSIS: In this community-based randomised controlled trial, 320 lactating women from Kampong Thom, Cambodia will be randomised to one of four groups to consume one capsule daily containing 0, 1.2, 2.4 or 10 mg thiamine as thiamine hydrochloride, between 2 and 24 weeks postnatal. The primary objective is to estimate the dose where additional maternal intake of thiamine no longer meaningfully increases infant thiamine diphosphate concentrations 24 weeks postnatally. At 2, 12 and 24 weeks, we will collect sociodemographic, nutrition and health information, a battery of cognitive assessments, maternal (2 and 24 weeks) and infant (24 weeks only) venous blood samples (biomarkers: ThDP and transketolase activity) and human milk samples (also at 4 weeks; biomarker: milk thiamine concentrations). All participants and their families will consume study-provided salt ad libitum throughout the trial, and we will measure salt disappearance each fortnight. Repeat weighed salt intakes and urinary sodium concentrations will be measured among a subset of 100 participants. Parameters of Emax dose-response curves will be estimated using non-linear least squares models with both 'intention to treat' and a secondary 'per-protocol' (capsule compliance ≥80%) analyses. ETHICS AND DISSEMINATION: Ethical approval was obtained in Cambodia (National Ethics Committee for Health Research 112/250NECHR), Canada (Mount Saint Vincent University Research Ethics Board 2017-141) and the USA (University of Oregon Institutional Review Board 07052018.008). Results will be shared with participants' communities, as well as relevant government and scientific stakeholders via presentations, academic manuscripts and consultations. TRIAL REGISTRATION NUMBER: NCT03616288.
Subject(s)
Breast Feeding , Milk, Human/metabolism , Sodium/urine , Thiamine Pyrophosphate/metabolism , Thiamine/administration & dosage , Adult , Cambodia , Cognition , Dietary Supplements , Double-Blind Method , Female , Humans , Infant , Infant, Newborn , Lactation , Sodium Chloride, Dietary , Thiamine/metabolism , Thiamine Deficiency/prevention & control , Transketolase/metabolismABSTRACT
Every year, sepsis affects nearly 30 million people worldwide, with current annual estimates reporting as many as 6 million deaths. To combat the staggering number of patients who are affected by sepsis, clinicians continue to investigate novel treatment approaches. One treatment approach that has gained interest is the role that vitamins and nutrients play in the body's response to sepsis. Thiamine, in particular, has been studied because of its role in glucose metabolism and lactate production. This review provides a summary of the current literature surrounding the use of thiamine in the treatment of sepsis and describes the function of this essential nutrient in sepsis pathology. We also aim to provide clinicians with the necessary understanding to recognize the potential for thiamine deficiency, as well as detail the role of thiamine supplementation in the treatment of sepsis.
Subject(s)
Sepsis/drug therapy , Thiamine/therapeutic use , Humans , Sepsis/complications , Thiamine Deficiency/prevention & controlABSTRACT
Sepsis is defined as the dysregulated host response to an infection resulting in life-threatening organ dysfunction. The metabolic demand from inefficiencies in anaerobic metabolism, mitochondrial and cellular dysfunction, increased cellular turnover, and free-radical damage result in the increased focus of micronutrients in sepsis as they play a pivotal role in these processes. In the present review, we will evaluate the potential role of micronutrients in sepsis, specifically, thiamine, l-carnitine, vitamin C, Se and vitamin D. Each micronutrient will be reviewed in a similar fashion, discussing its major role in normal physiology, suspected role in sepsis, use as a biomarker, discussion of the major basic science and human studies, and conclusion statement. Based on the current available data, we conclude that thiamine may be considered in all septic patients at risk for thiamine deficiency and l-carnitine and vitamin C to those in septic shock. Clinical trials are currently underway which may provide greater insight into the role of micronutrients in sepsis and validate standard utilisation.
Subject(s)
Ascorbic Acid/therapeutic use , Carnitine/therapeutic use , Deficiency Diseases/prevention & control , Selenium/therapeutic use , Sepsis/drug therapy , Thiamine/therapeutic use , Vitamin D/therapeutic use , Deficiency Diseases/etiology , Dietary Supplements , Humans , Micronutrients/therapeutic use , Nutritional Status , Sepsis/complications , Shock, Septic/drug therapy , Thiamine Deficiency/etiology , Thiamine Deficiency/prevention & controlABSTRACT
Starting with a brief history of beriberi and the discovery that thiamin deficiency is its cause, the symptoms and signs are reviewed. None are pathognomonic. The disease has a low mortality and a long morbidity. The appearance of the patient can be deceptive, often being mistaken for psychosomatic disease in the early stages. The chemistry of thiamin and the laboratory methodology for depicting its deficiency are outlined. The diseases associated with thiamin deficiency, apart from malnutrition, include a number of genetically determined conditions where mutations, either in the cofactor relationship or a transporter, provide the etiology. It is emphasized that such mutations are often epigenetically responsive to megadoses of thiamin or one of its derivatives. The use of thiamin in clinical practice requires a high index of suspicion on the part of the clinician since it has a part to play in eating disorders, diabetes, neurodegenerative disease, and cancer. A high rate of critical illness and postsurgery thiamin deficiency have been reported, particularly those associated with gastrointestinal bypass. Emphasis is placed on thiamin deficiency as a major cause of asymmetric dysautonomia, because of the high degree of sensitivity to thiamin deficiency in the brainstem, cerebellum, and hypothalamus. The relationship of thiamin with regional pain syndrome, eosinophilic esophagitis, its analgesic capacity, and its preventive use in obstetrics is raised as a potential issue. The role of thiamin in SIDS and autism is outlined. It is emphasized that megadose thiamin is being used as a drug, either in stimulating the damaged cofactor/enzyme combination, or mitochondria.
Subject(s)
Thiamine Deficiency/prevention & control , Thiamine/administration & dosage , Thiamine/pharmacology , Diet , Genetic Predisposition to Disease , Humans , Stress, Physiological , Thiamine Deficiency/epidemiology , Thiamine Deficiency/etiology , Thiamine Deficiency/genetics , Vitamins/administration & dosage , Vitamins/pharmacologyABSTRACT
Background: Traditionally, vitamin B1 status is assessed by a functional test measuring erythrocyte transketolase (ETK) activity or direct measurement of erythrocyte thiamine diphosphate (eThDP) concentration. However, such analyses are logistically challenging, and do not allow assessment of vitamin B1 status in plasma/serum samples stored in biobanks. Using a multiplex assay, we evaluated plasma concentrations of thiamine and thiamine monophosphate (TMP), as alternative, convenient measures of vitamin B1 status. Methods: We investigated the relationships between the established biomarker eThDP and plasma concentrations of thiamine and TMP, and compared the response of these thiamine forms to thiamine fortification using samples from 196 healthy Cambodian women (aged 18-45 years.). eThDP was measured by high performance liquid chromatography with fluorescence detection (HPLC-FLD) and plasma thiamine and TMP by high performance liquid chromatography-tandem mass spectrometry (LC-MS/MS). Results: Plasma thiamine and TMP correlated significantly with eThDP at baseline and study-end (p < 0.05). Among the fortification groups, the strongest response was observed for plasma thiamine (increased by 266%), while increases in plasma TMP (60%) and eThDP (53%) were comparable. Conclusions: Plasma thiamine and TMP correlated positively with eThDP, and all thiamine forms responded significantly to thiamine intervention. Measuring plasma concentrations of thiamine forms is advantageous due to convenient sample handling and capacity to develop low volume, high-throughput, multiplex assays.
Subject(s)
Erythrocytes/chemistry , Food, Fortified , Thiamine Deficiency/prevention & control , Thiamine Pyrophosphate/metabolism , Thiamine/blood , Thiamine/pharmacology , Adult , Asian People , Cambodia , Chromatography, Liquid , Female , Humans , Tandem Mass Spectrometry , Thiamine Deficiency/epidemiology , Thiamine Pyrophosphate/chemistryABSTRACT
OBJECTIVE: The aim of the study was to use linear programming (LP) analyses to adapt New Complementary Feeding Guidelines (NCFg) designed for infants aged 6 to 12 months living in poor socioeconomic circumstances in Bogota to ensure dietary adequacy for young children aged 12 to 23 months. DESIGN: A secondary data analysis was performed using dietary and anthropometric data collected from 12-month-old infants (nâ=â72) participating in a randomized controlled trial. LP analyses were performed to identify nutrients whose requirements were difficult to achieve using local foods as consumed; and to test and compare the NCFg and alternative food-based recommendations (FBRs) on the basis of dietary adequacy, for 11 micronutrients, at the population level. RESULTS: Thiamine recommended nutrient intakes for these young children could not be achieved given local foods as consumed. NCFg focusing only on meat, fruits, vegetables, and breast milk ensured dietary adequacy at the population level for only 4 micronutrients, increasing to 8 of 11 modelled micronutrients when the FBRs promoted legumes, dairy, vitamin A-rich vegetables, and chicken giblets. None of the FBRs tested ensured population-level dietary adequacy for thiamine, niacin, and iron unless a fortified infant food was recommended. CONCLUSIONS: The present study demonstrated the value of using LP to adapt NCFg for a different age group than the one for which they were designed. Our analyses suggest that to ensure dietary adequacy for 12- to 23-month olds these adaptations should include legumes, dairy products, vitamin A-rich vegetables, organ meat, and a fortified food.
Subject(s)
Food, Fortified/statistics & numerical data , Infant Nutritional Physiological Phenomena , Micronutrients/deficiency , Recommended Dietary Allowances , Age Factors , Case-Control Studies , Colombia , Female , Food, Fortified/analysis , Humans , Infant , Infant Formula/analysis , Infant Nutrition Disorders/prevention & control , Iron, Dietary , Linear Models , Male , Micronutrients/administration & dosage , Milk, Human , Niacin/deficiency , Poverty , Thiamine/administration & dosage , Thiamine Deficiency/prevention & controlSubject(s)
Diet , Nutritional Requirements , Recommended Dietary Allowances , Thiamine Deficiency , Thiamine , Adolescent , Adult , Child , Child, Preschool , Humans , Infant , Infant, Newborn , Thiamine/administration & dosage , Thiamine/therapeutic use , Thiamine Deficiency/complications , Thiamine Deficiency/prevention & control , Young AdultABSTRACT
To evaluate the effects of thiamine on physiological changes and spawning performance of Sterlet sturgeon Acipenser ruthenus, 45 farmed female fish (698.6±8.9g) were randomly distributed in 9 tanks (1000L) and fed a diet with 1g/kg of an anti-thiamine drug. This was provided for 5 months prior to spawning. Thiamine hydrochloride was intraperitoneally injected to fish at three different doses: 0 (T0, as control), 5 (T5) and 50 (T50) mg/kg body weight at days 30, 90 and 150 after the experiment started. After five months, the results showed no significant differences in weight gain and hemoglobin level, but hematocrit significantly increased in T5 group. There was no significant difference in glucose-6-phosphate dehydrogenase and estradiol-17ß, but testosterone was significantly increased in the T50 group. Total thiamine concentration in the eggs was significantly higher in T50 than that detected in the control group. Fecundity and larval mortality at 6day post hatch (dph) showed no significant differences among treatments, while the number of eggs per gram was significantly lower in T0 than that observed in T50. Larval weights at 1 (11.6mg) and 6 (23.1mg) dph and larval lengths at 6 (15.6mm) dph were significantly affected by the treatment with the highest level of thiamine injection (T50). Diseases symptoms such as yolk sac deformation, erratic pattern of swimming, and loss of equilibrium were observed at 4 dph in T0 and T5 groups. The overall results revealed that thiamine injection has positive effects on reproductive performance in the sturgeon and the negative impacts of anti-thiamine in the offspring can be reduced by the injection of this vitamin to the broodstock.
Subject(s)
Fishes/physiology , Reproduction/drug effects , Thiamine/pharmacology , Animals , Dose-Response Relationship, Drug , Estradiol/blood , Estradiol/metabolism , Female , Fertility/drug effects , Glucosephosphate Dehydrogenase/genetics , Glucosephosphate Dehydrogenase/metabolism , Larva/drug effects , Larva/physiology , Maternal Nutritional Physiological Phenomena , Ovum , Reproduction/physiology , Testosterone/blood , Testosterone/metabolism , Thiamine/administration & dosage , Thiamine Deficiency/prevention & control , Thiamine Deficiency/veterinaryABSTRACT
IMPORTANCE: Infantile beriberi, a potentially fatal disease caused by thiamine deficiency, remains a public health concern in Cambodia and regions where thiamine-poor white rice is a staple food. Low maternal thiamine intake reduces breast milk thiamine concentrations, placing breastfed infants at risk of beriberi. OBJECTIVE: To determine if consumption of thiamine-fortified fish sauce yields higher erythrocyte thiamine diphosphate concentrations (eTDP) among lactating women and newborn infants and higher breast milk thiamine concentrations compared with a control sauce. DESIGN, SETTING, AND PARTICIPANTS: In this double-blind randomized clinical trial, 90 pregnant women were recruited in the Prey Veng province, Cambodia. The study took place between October 2014 and April 2015. INTERVENTIONS: Women were randomized to 1 of 3 groups (n = 30) for ad libitum fish sauce consumption for 6 months: control (no thiamine), low-concentration (2 g/L), or high-concentration (8 g/L) fish sauce. MAIN OUTCOMES AND MEASURES: Maternal eTDP was assessed at baseline (October 2014) and endline (April 2015). Secondary outcomes, breast milk thiamine concentration and infant eTDP, were measured at endline. RESULTS: Women's mean (SD) age and gestational stage were 26 (5) years and 23 (7) weeks, respectively. April 2015 eTDP was measured among 28 women (93%), 29 women (97%), and 23 women (77%) in the control, low-concentration, and high-concentration groups, respectively. In modified intent-to-treat analysis, mean baseline-adjusted endline eTDP was higher among women in the low-concentration (282nM; 95% CI, 235nM to 310nM) and high-concentration (254nM; 95% CI, 225nM to 284nM) groups compared with the control group (193nM; 95% CI, 164nM to 222M; P < .05); low-concentration and high-concentration groups did not differ (P = .19). Breast milk total thiamine concentrations were 14.4 µg/dL for the control group (95% CI, 12.3 µg/dL to 16.5 µg/dL) (to convert to nanomoles per liter, multiply by 29.6); 20.7 µg/dL for the low-concentration group (95% CI, 18.6 µg/dL to 22.7 µg/dL ); and 17.7 µg/dL for the high-concentration group (95% CI, 15.6 µg/dL to 19.9 µg/dL). Mean (SD) infant age at endline was 16 (8) weeks for the control group, 17 (7) weeks for the low-concentration group, and 14 (8) for the high-concentration group. Infant eTDP was higher among those in the high-concentration group (257nM; 95% CI, 222nM to 291nM; P < .05) compared with the low-concentration (212nM; 95% CI, 181nM to 244nM) and control (187nM; 95% CI, 155nM to 218nM) groups. CONCLUSIONS AND RELEVANCE: Compared with women in the control group, women who consumed thiamine-fortified fish sauce through pregnancy and early lactation had higher eTDP and breast milk thiamine concentrations and their infants had higher eTDP, which was more pronounced in the high group. Thiamine-fortified fish sauce has the potential to prevent infantile beriberi in this population. TRIAL REGISTRATION: Clinicaltrials.gov Identifier: NCT02221063.
Subject(s)
Dietary Supplements , Edetic Acid/therapeutic use , Food, Fortified , Pregnancy Complications/prevention & control , Thiamine Deficiency/prevention & control , Adult , Anemia, Iron-Deficiency/prevention & control , Animals , Asian People , Beriberi/prevention & control , Cambodia , Female , Fishes , Humans , Maternal Nutritional Physiological Phenomena , Pregnancy , Prenatal Care , Rural Population , Young AdultABSTRACT
OBJECTIVE: To determine thiamine-dependent enzyme activities in various tissue samples of Pacific harbor seals (Phoca vitulina) and thiaminase activities in dietary fish. DESIGN: Cross-sectional study. ANIMALS: 11 Pacific harbor seals with thiamine deficiency and 5 control seals. PROCEDURES: Seals underwent evaluation to rule out various diseases and exposure to toxins. For seals that died, measurement of thiamine-dependent enzymes in liver and brain samples and determination of mitochondrial DNA (mtDNA) copy number in liver, brain, and muscle samples were performed. Thiaminase activity in dietary fish was determined. RESULTS: 8 seals with thiamine deficiency died. Affected seals typically had acute neurologic signs with few nonspecific findings detected by means of clinicopathologic tests and histologic examination of tissue samples. Thiamine-dependent enzyme activities in liver samples of affected seals were significantly lower than those in control liver samples. The primary activation ratios and latencies for enzymes indicated that brain tissue was more affected by thiamine deficiency than liver tissue. Activities of pyruvate dehydrogenase were more affected by thiamine deficiency than those of transketolase and ketoglutarate dehydrogenase. For control seals, the mtDNA copy number in muscle samples was significantly lower than that for affected seals; conversely, the copy number in control liver samples was significantly greater than that of affected seals. Thiaminase activity was substantially higher in smelt than it was in other types of dietary fish. CONCLUSIONS AND CLINICAL RELEVANCE: Results of analyses in this study confirmed a diagnosis of thiamine deficiency for affected seals resulting from high thiaminase activity in dietary fish, inadequate vitamin administration, and increased thiamine demand caused by pregnancy and lactation.
Subject(s)
Animal Feed/analysis , Fishes , Phoca , Thiamine Deficiency/veterinary , Thiamine/administration & dosage , Animal Husbandry , Animal Nutritional Physiological Phenomena , Animals , Animals, Zoo , DNA, Mitochondrial , Diet/veterinary , Female , Lactation/physiology , Male , Muscle, Skeletal , Pregnancy , Thiamine Deficiency/pathology , Thiamine Deficiency/prevention & controlABSTRACT
Roux-en-Y gastric bypass is the most commonly performed bariatric procedure. It is associated with nutritional deficiencies due to gastric reduction, intestinal bypass, reduced caloric intake, avoidance of nutrient-rich foods, noncompliance with supplementation and poor food tolerability. Although there are multiple publications on this topic, there is a lack of consistent guidance for the healthcare practitioner caring for the bariatric patient. This article will encompass literature reviewing the pharmacotherapy approach to prevention and management of nutritional deficiencies since the American Society of Metabolic and Bariatric Surgery guidelines were published in 2008.